POS-VAP

Ventilator-Associated Pneumonia (VAP) is a frequent complication in mechanically-ventilated ICU patients and is often caused by multi-drug resistant bacteria. Distinguishing bacterial colonisation of the respiratory tract from infection of the lung tissue is extremely difficult with currently available diagnostic approaches resulting in an unnecessary use of broad-spectrum antibiotics in many patients, thereby enhancing antimicrobial resistance (AMR).

The primary objective of this study is to provide an infrastructure capable of rapidly implementing randomised controlled trials (RCTs) and other clinical trials related to prevention, diagnosis or treatment of VAP in ICUs. The secondary objectives include descriptive analyses related to patient characteristics, complications, outcome and risk factors.

Interested in collaborating on this study?

Updates

OCTOBER 2024 • Patient #4,000 was enrolled at University Hospital Gent in Belgium.

MAY 2024 • The study surpassed 3,000 enrolled patients in 10 months.

JANUARY 2024 • In a first for the ECRAID-Base project, POS-VAP reached the milestone of 2,000 enrolled patients.

SEPTEMBER 2023 • Patient #1,000 was enrolled at the Central University Hospital of Asturias, Spain. 

MAY 2023 • Patient #500 was enrolled at the Lille University Hospital Center, France. 

AUGUST 2022 • Patient enrolment has begun. The first patients were included at the Clinical Research Centre of Limoges. 

APRIL 2022 • The first round of site selection for POS-VAP has commenced with 13 confirmed sites. The team expects to start including patients for an observational study at the end of the summer.

This study is being conducted under the ECRAID-Base project which has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 965313.